On the stock market since 2015, it operates in the world of health and science. It has 20 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
The stock trades 15% below its peak. The market has trimmed its expectations for the company.
There is $328.1M in the vault; even if every debt were paid off, $322.8M would remain.
A loss of $94.3M against $0 in annual sales.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, CATB sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CATB is a high-risk stock — not yet profitable, and its future rides on its product catching on.